MedImmune licenses GSK mid-stage biotech drug

08/30/2005 | American City Business Journals

The Maryland biotech said it has acquired worldwide rights from GlaxoSmithKline to develop monoclonal antibodies targeting Staphylococcus bacteria. The drug candidates MedImmune has licensed include BSYX-A110, which is in Phase II trials for preventing bloodstream infections caused by staph in low-birthweight babies.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN